If you've ever wondered why some allergic reactions progress quickly and may even become fatal, a new research report published in the February 2009 issue of the Journal of Leukocyte Biology provides an important part of the answer.
In the report, scientists from Queen's University of Belfast, University of Oxford and Trinity College Dublin show for the first time that eotaxin, a chemical that helps immune cells locate the site of infection, blocks basic "fighter" cells from transforming into "seeker" dendritic cells, resulting in a heightened allergic response.
"Our study reveals a new role for the chemokine eotaxin in controlling immune cell types at the site of allergic reaction," said Nigel Stevenson, a researcher involved in the study. "These findings are crucial for our understanding of allergic responses and may be instrumental for the design of new allergy drugs."
Stevenson and colleagues made this discovery by using immune cells grown in the lab and from healthy volunteers. Then the researchers mimicked what occurs during an allergic reaction by treating the cells with eotaxin, which was previously believed to only attract immune cells during an allergic reaction. Through a series of laboratory procedures, they tracked changes in immune cell type and found that eotaxin inhibits monocytes becoming dendritic cells (that find foreign invaders so other immune cells can neutralize them), resulting in more "fighter" cells being present during an allergic response. This discovery shows how and why eotaxin plays an important role in the severity of allergic reactions and may be a target for an entirely new class of allergy medications.
"For some people, allergies are very serious often debilitating problem, forcing them to be extremely careful about what they breathe, touch, or eat," said E. John Wherry, Deputy Editor of the Journal of Leukocyte Biology. "The insights from this work on the unexpected role of eotaxin should provide novel therapeutic opportunities for intervention during diseases like asthma, food allergies and other situations where unchecked allergic responses cause problems."
According to the U.S. Centers for Disease Control and Prevention Allergies, more than 50 million Americans suffer from allergies each year. Allergies are the 6th leading cause of chronic illness in the U.S., costing more than $18 billion. The most severe type of allergic reaction is called "anaphylaxis," which can be fatal.
The Journal of Leukocyte Biology (http://www.jleukbio.org) publishes peer-reviewed manuscripts on original investigations focusing on the cellular and molecular biology of leukocytes and on the origins, the developmental biology, biochemistry and functions of granulocytes, lymphocytes, mononuclear phagocytes and other cells involved in host defense and inflammation. The Journal of Leukocyte Biology is published by the Society for Leukocyte Biology.
Cody Mooneyhan | EurekAlert!
Further information:
http://www.faseb.org
http://www.jleukbio.org
Further reports about: > Allergic > Asthma > Leukocyte > Leukocyte Biology > allergic reaction > allergic responses > allergies > allergy medications > dendritic cells > eotaxin > food allergies > granulocytes > immune cell > lymphocytes > monocytes > mononuclear phagocytes > synthetic biology
One step closer to reality
20.04.2018 | Max-Planck-Institut für Entwicklungsbiologie
The dark side of cichlid fish: from cannibal to caregiver
20.04.2018 | Veterinärmedizinische Universität Wien
University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.
Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.
Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...
Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.
The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...
Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.
Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...
In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...
Anzeige
Anzeige
Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"
13.04.2018 | Event News
Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018
12.04.2018 | Event News
IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur
09.04.2018 | Event News
Magnetic nano-imaging on a table top
20.04.2018 | Physics and Astronomy
Start of work for the world's largest electric truck
20.04.2018 | Interdisciplinary Research
Atoms may hum a tune from grand cosmic symphony
20.04.2018 | Physics and Astronomy